CPIX vs HROW vs PRPH vs AYTU vs CODA

For growth investors, Harrow Health, Inc.

(HROW) is the stronger pick with 36. 4% revenue growth year-over-year, versus -84. 7% for ProPhase Labs, Inc. (PRPH). Coda Octopus Group, Inc. (CODA) offers the better valuation at 32. 2x trailing P/E (22. 5x forward), making it the more compelling value choice. Analysts rate Harrow Health, Inc. (HROW) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Coda Octopus Group, Inc.

is actually cheaper at 22. 5x.

Over the past 5 years, Harrow Health, Inc.

(HROW) delivered a total return of +378. 0%, compared to -97. 8% for Aytu BioPharma, Inc. (AYTU). Over 10 years, the gap is even starker: HROW returned +914. 3% versus AYTU's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Coda Octopus Group, Inc.

(CODA) is the lower-risk stock at 1. 00β versus ProPhase Labs, Inc. 's 2. 28β — meaning PRPH is approximately 127% more volatile than CODA relative to the S&P 500. On balance sheet safety, Coda Octopus Group, Inc. (CODA) carries a lower debt/equity ratio of 1% versus 5% for Harrow Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Harrow Health, Inc.

(HROW) is pulling ahead at 36. 4% versus -84. 7% for ProPhase Labs, Inc. (PRPH). On earnings-per-share growth, the picture is similar: Harrow Health, Inc. grew EPS 71. 4% year-over-year, compared to -166. 3% for ProPhase Labs, Inc.. Over a 3-year CAGR, HROW leads at 45. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Coda Octopus Group, Inc.

(CODA) is the more profitable company, earning 15. 5% net margin versus -788. 2% for ProPhase Labs, Inc. — meaning it keeps 15. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CODA leads at 17. 1% versus -570. 6% for PRPH. At the gross margin level — before operating expenses — CPIX leads at 85. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Coda Octopus Group, Inc.

(CODA) trades at 22. 5x forward P/E versus 82. 9x for Harrow Health, Inc. — 60. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HROW: 93. 8% to $75. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Coda Octopus Group, Inc.

(CODA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 00), +844. 4% 10Y return). ProPhase Labs, Inc. (PRPH) carries a higher beta of 2. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CODA: +844. 4%, PRPH: +37. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CPIX (Healthcare) and HROW (Healthcare) and PRPH (Healthcare) and AYTU (Healthcare) and CODA (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CPIX is a small-cap high-growth stock; HROW is a small-cap high-growth stock; PRPH is a small-cap quality compounder stock; AYTU is a small-cap quality compounder stock; CODA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.